Related Experiment Video

Updated: Feb 11, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Progress in Gene Therapy for Chronic Heart Failure

Zhi-Qiang Yin1, Wan-Hong Xing2

  • 1Shanxi Medical University, P.R.China.

The Heart Surgery Forum
|April 17, 2018
PubMed

Insights

Gene therapy offers a promising new treatment for chronic heart failure (CHF) by targeting cellular processes. This review explores advanced gene transfer technologies for improving cardiac function and survival rates.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Biotechnology

Background:

  • Chronic heart failure (CHF) remains a leading cause of death globally, with limited success from conventional treatments in improving long-term survival.
  • Novel pharmacologic and surgical interventions have not significantly extended five-year survival rates for CHF patients.
  • The development of recombinant DNA technology has paved the way for gene therapy as a potential alternative treatment for CHF.

Purpose of the Study:

  • To review various gene transfer technologies for treating ischemic heart disease (IHD) and heart failure (HF).
  • To discuss the advantages and disadvantages of vector-mediated cardiac gene delivery strategies.
  • To highlight high-efficiency molecular cardiac surgery delivery systems for gene therapy in CHF.

Main Methods:

  • Review of current research on gene therapy for advanced heart failure and ischemic heart disease.
  • Analysis of various genes, signal transduction pathways, and delivery methods used in cardiac gene therapy.
  • Focus on vector-mediated gene transfer strategies and cardiomyocyte transfection.

Main Results:

  • Gene therapy research has explored diverse genes, pathways, and delivery methods to treat advanced heart failure over the past two decades.
  • Current research in IHD focuses on angiogenesis, vascular environment modification, and endothelial function improvement using gene-coated devices.
  • Key goals of gene therapy for CHF include inhibiting apoptosis, reducing adverse remodeling, and enhancing contractility.

Conclusions:

  • Gene therapy presents a viable treatment alternative for CHF, leveraging advancements in myocardial metabolism and gene transfer.
  • Vector-mediated gene delivery offers potential benefits but requires careful consideration of advantages and disadvantages.
  • High-efficiency molecular cardiac surgery delivery systems are crucial for successful cardiomyocyte transfection in gene therapy for heart failure.

Keywords:
cardiac gene therapychronic heart failuregene delivery methodsmolecular cardiac surgery with recirculating delivery

More Related Videos

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.3K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K